Abstract: Methods and compositions for the treatment of treatment-resistant depression are described. More specifically, the invention demonstrates that intranasal administration of ketamine is effective to ameliorate the symptoms of depression in a patient who has not responded to an adequate trial of one antidepressant in the current episode and has recurrent or chronic depressive symptoms (>2 years).
Type:
Grant
Filed:
March 5, 2014
Date of Patent:
January 10, 2017
Assignees:
Icahn School of Medicine at Mount Sinai, Yale University, The United States of America, as represented by The Secretary, Department of Health and Human Services
Inventors:
Dennis S. Charney, Sanjay J. Mathew, Husseini K. Manji, Carlos A. Zarate, John H. Krystal
Abstract: The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blocker such as NaV1.3 and NaV1.7, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.
Abstract: The embodiments described herein include methods and formulations for treating lung and brain injury. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
Abstract: Solutions of testosterone for oromucosal administration providing an increase in serum testosterone levels in subjects deficient in endogenous testosterone levels, and therapeutic methods for providing an increase in serum testosterone levels and methods for treating a disease or a symptom associated with deficient endogenous levels of testosterone.
Type:
Grant
Filed:
August 9, 2011
Date of Patent:
November 22, 2016
Assignee:
INNOTESTO BVBA
Inventor:
Franciscus Wilhelmus Henricus Maria Merkus
Abstract: Sebum absorption compositions are disclosed which include (a) 1% to 20% by weight of the composition of a sebum absorption ingredient; and (b) 20% to 99% by weight of the composition of a volatile solvent.
Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt thereof. The present invention is directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylthio)alkylnitriles such as 3-(methylthio)propionitrile, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
Type:
Grant
Filed:
August 21, 2015
Date of Patent:
October 25, 2016
Assignee:
OLATEC THERAPEUTICS LLC
Inventors:
Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse
Abstract: The preset invention relates to a method for treating inflammation comprising administering a subject in need thereof with a therapeutically effective amount of polyenylpyrrole derivatives of formula (I) or a pharmaceutically acceptable salt thereof.
Abstract: Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.
Abstract: Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17?-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration, and include effects on stroke and TBI.
Type:
Grant
Filed:
December 21, 2012
Date of Patent:
September 20, 2016
Assignee:
The Population Council, Inc.
Inventors:
Regine Sitruk-Ware, Michael Maria Helmut Schumacher, Roberta Brinton, Martine El-Etr, Abdelmouman Ghoumari, Rachida Guennoun
Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.
Type:
Grant
Filed:
December 3, 2015
Date of Patent:
September 13, 2016
Assignee:
OLATEC THERAPEUTICS LLC
Inventors:
Joseph P. St. Laurent, Gerald S. Jones, David M. Breese
Abstract: This invention relates to a compound of formula I and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
Type:
Grant
Filed:
July 31, 2015
Date of Patent:
September 13, 2016
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Matthias Grauert, Ralf Anderskewitz, Achim Bixenmann, Marc Grundl, Peter Wilhelm Haebel, Alexander Pautsch
Abstract: The present invention relates to one or more of the phytocannabinoids tetrahydrocannabivarin (THCV); cannabigerol (CBG); cannabichromene (CBC); and cannabidivarin (CBDV) for use in the treatment of intestinal inflammatory diseases. Preferably the intestinal inflammatory disease is either ulcerative colitis or Crohn's disease.
Type:
Grant
Filed:
November 21, 2012
Date of Patent:
August 23, 2016
Assignee:
GW Pharma Limited
Inventors:
Angelo Antonio Izzo, Francesca Borrelli, Stephen Wright
Abstract: Provided herein are methods for modulating immune responses to a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof. Also provided herein are methods for treating, preventing, ameliorating, and/or delaying the onset of one or more symptoms associated with or resulting from a respiratory viral infection (e.g., influenza, rhinovirus, coronavirus, or paramyxovirus) in a subject, wherein the methods comprise administering to the subject a compound (e.g., a PDE4 modulator or an immunomodulatory compound), or a pharmaceutically acceptable salt, solvate, hydrate, or stereoisomer thereof.
Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3K activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3K activity, are described herein.
Type:
Grant
Filed:
November 12, 2012
Date of Patent:
August 2, 2016
Assignees:
Intellikine LLC, Sigma-Aldrich Company Limited
Inventors:
Pingda Ren, Michael Martin, Christopher Peter Worrall, Susanna del Rio Gancedo
Abstract: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
Abstract: A therapy for renal diseases, in particular renal diseases, which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, palmitoylethanolamide and diethanolamide of fumaric acid are used in the treatment of renal diseases, in particular those caused by dysmetabolic diseases or by toxic or chemotherapy agents, such as platinum derivatives. Palmitoylethanolamide is used preferably in micronized or ultra-micronized form. Diethanolamide of fumaric acid is used preferably in aqueous solution.
Type:
Grant
Filed:
November 7, 2014
Date of Patent:
August 2, 2016
Assignee:
Epitech Group S.r.l.
Inventors:
Francesco Della Valle, Raffaele Migliaccio, Maria Federica Della Valle
Abstract: Methods of treating or suppressing pervasive developmental disorders (PDDs) including; autistic disorder, Asperger's syndrome, childhood disintegrative disorder (CDD), Rett's disorder, and PDD-not otherwise specified (PDD-NOS) or attention deficit/hyperactivity disorder (ADHD) comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds as disclosed herein.
Abstract: The method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of estrogen replacement therapy to a patient in need thereof to promote wound healing. Alternatively, the method of treating diabetes-related impaired wound healing includes the step of administering an effective amount of a TNF-? inhibitor to a patient in need thereof to promote wound healing. The method of treating diabetes-related impaired wound healing may also include both the step of administering an effective amount of estrogen replacement therapy and administering an effective amount of a TNF-? inhibitor to a patient in need thereof to promote wound healing.
Abstract: Disclosed is a method of remyelinating axons with 6-substituted estradiol compounds of the formula The methods can be used to treat a variety of demyelinating diseases.